The Catalyst

Most Recent Posts


It is worth checking out an interesting blog piece that ran in The Washington Post over the weekend about the government funding military innovation. Oftentimes, people mistakenly believe that the government also funds the majority of biopharmaceutical innovation, but this couldn't be further from the truth.

01.06.12 | By Greg Lopes

An article in yesterday's Wall Street Journal (subscription required) presents some exciting news on the fight against HIV/AIDS. New research, to be published Wednesday in the journal Nature, shows that some investigational new vaccines may protect monkeys against a powerful strain of the virus.


Evidence of recent progress in our collective fight against cancer continued yesterday with the American Cancer Society's annual report, Cancer Statistics, 2012. According to ACS, between 1990/1991 and 2008, overall death rates from cancer fell by approximately 23 percent in men and 15 percent in women - meaning that more than a million deaths from cancer were prevented.

01.05.12 | By Kate Connors

Associated Press reporter Linda Johnson wrote a great article this week (find it here on the Chicago Tribune's site) about medication adherence. I hate to say it's an exhaustive commentary on adherence, since that's a pretty big issue to cover, but she captures a lot - including, importantly, tips about programs, apps and resources to help patients adhere.

For example:


For some important perspective on some of challenges and questions we at PhRMA will be focusing on during 2012 and into the future, take a look at PhRMA President John Castellani's contribution to Chain Drug Review's annual "Pharmacy Outlook '12" issue.

01.03.12 | By Kate Connors

In case you haven't yet heard, FDA recently launched a blog, FDA Voice, as part of its recent Website redesign. Kicked off by a post from Commissioner Margaret Hamburg, the blog promises to "give you insights on some of the most pressing public health issues of the day."

After a momentous year, Washington is readying itself for holiday vacation. There's no better indication than my traffic-free commute over the bridge - it was, dare I say, relaxing. I welcome the slower pace not just for the liberation from gridlock; it's a chance to reflect on the year. And on the biopharmaceutical industry front, it was 12 months of major medical advances.
12.15.11 | By Kate Connors
On the Pharmalot blog, Ed Silverman published an interesting op-ed by Brian Reid, a social media expert with WCG, about the lack of FDA guidance on social media.
Here at PhRMA, I'm known as a bit of a road warrior. There's nothing I enjoy more than leaving Washington, D.C. in the rear view mirror to travel around the country on behalf of the biopharmaceutical research industry to meet with reporters, legislators, local business leaders and, sometimes, even university research officials. We've got a story to tell and as a hairy cell leukemia survivor saved by a chemotherapy and some powerful antibiotics, I'm happy to tell it.
12.14.11 | By Preet Bilinski
Hear from Dr. John Pottage, the chief scientific and medical officer for ViiV Healthcare, who has been in the battle against HIV/AIDS since before we even identified the disease. He discusses the improvements that new medicines and therapies have made for patients. But with a new infection occurring every nine and a half minutes, more needs to be done. America's biopharmaceutical companies agree and are continuing their fight against this epidemic with 88 medicines and vaccines in development for HIV/AIDS.
12.13.11 | By Kate Connors
In The Hill's CongressBlog, PhRMA President and CEO John J. Castellani had an op-ed today about how our federal efforts to stimulate economic growth will undoubtedly lack the momentum they need without a related emphasis on exports - and the biopharmaceutical sector, already a major generator of exports, can help. But we need support.
I recommend taking a look at the new G-FINDER: YEAR 4 report on Neglected Disease Research and Development. Unfortunately, the report describes how funding for neglected disease research by governments and many NGOs declined over the last year. The one exception, the report indicates, is that the pharmaceutical research industry's investment in these diseases went up.
Saw this story about possible new therapy to reverse hemophilia in a couple of outlets over the weekend and wanted to pass it along.
12.09.11 | By Preet Bilinski
I recommend taking a look at the Business World Weekender discussion for World AIDs Day: "Getting to Zero." The campaign's goal is to have zero new infections, zero discrimination and zero AIDS related deaths. While the article focuses on the Asia Pacific region it is important to keep in mind that this is a disease without boundaries.
12.07.11 | By Kate Connors
Earlier this week, HHS Secretary Kathleen Sebelius gave a speech about the use of mobile information technology in healthcare. She lauded the advancements made in this field, from health IT in doctors' offices to iPad apps that help patients quit smoking.